Gold Nanorods for Doxorubicin Delivery: Numerical Analysis of Electric Field Enhancement, Optical Properties and Drug Loading/Releasing Efficiency.
COMSOL Multiphysics
doxorubicin
drug delivery
gold nanorods
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
26 Feb 2022
26 Feb 2022
Historique:
received:
06
12
2021
revised:
12
02
2022
accepted:
19
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The optical properties and electric field enhancement of gold nanorods for different cases were investigated in this study. The numerical analysis was carried out to understand the functionality and working of gold nanorods, while the experimental portion of the work was focused on the efficiency of gold nanorods for targeted drug delivery. COMSOL Multiphysics was used for numerical analysis. The theoretical results suggest the use of gold nanorods (AuNRs) for anticancer applications. The resonance peaks for gold nanorods of 10 nm diameter were observed at 560 nm. The resonance peaks shifted towards longer wavelengths with an increase in nanorod size. The resonance peaks showed a shift of 140 nm with a change in nanorod length from 25 to 45 nm. On the experimental side, 22 nm, 35 nm and 47 nm long gold nanorods were produced using the seed-mediated growth method. The surface morphology of the nanorods, as well as their optical characteristics, were characterized. Later, gold nanorods were applied to the targeted delivery of the doxorubicin drug. Gold nanorods showed better efficiency for doxorubicin drug loading time, release time, loading temperature, and release temperature. These results reveal that AuNRs@DA possess good ability to load and deliver the drug directly to the tumorous cells since these cells show high temperature and acidity.
Identifiants
pubmed: 35268995
pii: ma15051764
doi: 10.3390/ma15051764
pmc: PMC8911263
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nature. 2008 Jun 5;453(7196):757-60
pubmed: 18528390
Mater Sci Eng C Mater Biol Appl. 2018 Feb 1;83:90-98
pubmed: 29208292
Chem Soc Rev. 2008 May;37(5):885-97
pubmed: 18443674
Nanomedicine (Lond). 2007 Oct;2(5):681-93
pubmed: 17976030
J Phys Chem Lett. 2012 May 17;3(10):1248-52
pubmed: 26286766
Beilstein J Nanotechnol. 2021 Mar 31;12:295-303
pubmed: 34012759
Adv Mater. 2010 Apr 22;22(16):1805-25
pubmed: 20512954
Nanomaterials (Basel). 2021 Nov 14;11(11):
pubmed: 34835828
Int J Nanomedicine. 2017 Aug 24;12:6205-6218
pubmed: 28883730
Cancer Res. 1971 Jan;31(1):32-7
pubmed: 5099799
Chem Rev. 2012 Apr 11;112(4):2373-433
pubmed: 22204603
Chem Soc Rev. 2012 Feb 7;41(3):1191-217
pubmed: 21947414
Materials (Basel). 2018 Feb 11;11(2):
pubmed: 29439458
Materials (Basel). 2022 Jan 24;15(3):
pubmed: 35160822
Nanotechnology. 2011 Dec 9;22(49):494002
pubmed: 22101232
J Drug Target. 1998;5(3):171-9
pubmed: 9606007
Materials (Basel). 2017 Feb 20;10(2):
pubmed: 28772563
Support Care Cancer. 2012 Mar;20(3):653-6
pubmed: 22089429
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
ACS Appl Mater Interfaces. 2016 Sep 21;8(37):24368-84
pubmed: 27564325
J Control Release. 2011 Mar 30;150(3):318-25
pubmed: 21115079
Langmuir. 2004 Jul 20;20(15):6414-20
pubmed: 15248731
Materials (Basel). 2017 Nov 30;10(12):
pubmed: 29189739
Sci Rep. 2017 Feb 22;7:43006
pubmed: 28223691
Materials (Basel). 2021 Jul 02;14(13):
pubmed: 34279276
J Occup Med Toxicol. 2007 Dec 01;2:16
pubmed: 18053152
Biomaterials. 2015 Sep;63:115-27
pubmed: 26093792
Histochem Cell Biol. 1996 Jul;106(1):1-8
pubmed: 8858362
Biosens Bioelectron. 2017 Oct 15;96:300-307
pubmed: 28511113
ACS Nano. 2008 Apr;2(4):677-86
pubmed: 19206598
Chem Rev. 2011 Jun 8;111(6):3888-912
pubmed: 21434605